Clinical Trials Logo

Cardiomyopathy, Dilated clinical trials

View clinical trials related to Cardiomyopathy, Dilated.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT03071653 Suspended - Clinical trials for Dilated Cardiomyopathy

Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study

LCSD
Start date: November 24, 2016
Phase: Phase 2
Study type: Interventional

A randomized controlled trial to test the potential safety and efficacy of LCSD in patients with heart failure due to non-ischemic and ischemic cardiomyopathy at the University of Cape Town. Left Cardiac Sympathetic Denervation (LCSD) is a surgical intervention that modulates the autonomic innervation of the cardiac system. This is important because: a] sympathetic and parasympathetic tone has a profound effect on the threshold for ventricular tachyarrhythmias-the main cause of sudden cardiac death in this population; and b] autonomic dysfunction (which is characterized by an imbalance between sympathetic and parasympathetic activation), plays an important detrimental role in the pathophysiology and progression of heart failure.

NCT ID: NCT01504594 Suspended - Clinical trials for Cardiomyopathy, Dilated

Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether an autologous stem cell infusion through catheterism is safe and effective in the treatment of pediatric dilated cardiomyopathy. Process: 1. Primary Evaluation - Clinical History - Echocardiogram to evaluate ejection fraction and other parameters 2. Signing of Informed Consent and clearing doubts 3. Bone Marrow stimulation for 3 consecutive days with G-CSF (Granulocyte Colony Stimulating Factor) applied subcutaneously 4. On the 4th day, in operation room and under sedation: Bone Marrow Harvest performed by hematologists through posterior iliac crests(amount calculated at 8cc/kg, without exceeding 150ml). 5. Recovery room with family members while the cells are being processed in the Hematology Laboratory. 6. Approximately 3 hours after the 1st procedure, the patient re-enters the operation room, which is equipped for cardiac catheterization, so that cardiologists infuse the stem cells through the femoral artery into the coronary arteries which irrigate the heart´s muscle fibers. 7. Patient goes back to the recovery area until the anesthesia effect is gone and can tolerate oral liquids. 8. Clinical and echocardiographic follow-ups at 6 weeks and 6 months after the procedure.